MoFo News Item

MoFo Advises Krystal Biotech in Underwritten Common Stock Offering

04 Feb 2021

MoFo represented Krystal Biotech, Inc. in its $143.75 million common stock offering at $65 per share. Goldman Sachs & Co. LLC, Cowen, and Evercore ISI acted as joint book-running managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering and Ladenburg Thalmann & Co. Inc. and SMBC Nikko acted as co-managers. 

The deal team was led by John Campbell and included corporate associates John Hensley, Hillary Daniels, and Ken Taylor. Partner Jim Mullen and associate Bu Yin provided intellectual property counsel on the matter. 

Krystal (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. MoFo has represented the company in corporate and intellectual property matters since its inception in 2016.

Read a news release relating to the offering.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.